Skip to main content
padlock icon - secure page this page is secure

Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older

Buy Article:

$52.00 + tax (Refund Policy)

A multicentre prospective non‐randomised study of de novo acute myeloid leukaemia (AML) in patients aged ≥70 yr was designed to reduce toxicity and achieve acceptable complete remission (CR) rates.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: AML; elderly patients; intermediate dose cytarabine; outpatient management

Document Type: Research Article

Publication date: December 1, 2015

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more